CNS Pharmaceuticals Inc. CNSP Archives - Page 17 of 22

MondayMay 10, 2021 2:28 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) on Track to Begin Potentially Pivotal Phase 2 GBM Trial This Quarter for Berubicin

During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%) Additional research to be conducted by sublicensee partner WPD Pharmaceuticals, Inc. in Poland, including the first-ever pediatric trial The glioblastoma multiforme (“GBM”) treatment market is expected to reach $1.4 billion by 2027 CNS Pharma positioning to secure a leading role in treating GBM A potentially pivotal Phase 2 trial is on track to commence during Q2 2021 by CNS Pharmaceuticals (NASDAQ: CNSP). This trial is currently…

ThursdayApr 22, 2021 2:41 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Start Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated when another company completed a small Phase 1 trial well over a decade ago in which 44% of patients saw their disease stabilize or improve. One Berubicin patient was living cancer-free as of the most recent medical assessment in November, nearly 15 years after the Phase 1 trial (https://ibn.fm/JnFSS). “CNS now hopes to advance Berubicin to commercial production, with the…

FridayApr 16, 2021 1:15 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the…

ThursdayApr 08, 2021 2:19 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals approximately 15 years ago. One of the trial participants has remained alive and cancer-free as of the most recent evaluation late last year, while two other patients in the small study saw reductions of greater than 25% (one being an 80% reduction) in the…

WednesdayApr 07, 2021 2:42 pm

Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial

Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed A recent study by the Washington University School of Medicine found that the length of survivability appeared to improve when the standard chemotherapy regimen was given in the morning instead of the evening Brain cancer drug developer CNS Pharmaceuticals is also working on a solution to improve the quality of GBM care, seeing hope in its lead drug candidate, Berubicin, which showed promise in a small Phase 1 trial nearly 15…

MondayMar 29, 2021 12:37 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021

GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021 The company is continuing its pre-clinical work on WP1244 during 2021 and 2022 CNS Pharmaceuticals participated in two virtual conferences during March, spreading awareness about Berubicin and the GBM indicator CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced multiple value-driving milestones for its lead drug candidate…

ThursdayMar 25, 2021 2:19 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug candidate, Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol. The protocol will be used in the planned forthcoming Berubicin clinical trial in adults with glioblastoma multiforme (“GBM”). This new development set the wheels in motion for the eventual approval of WPD’s studies — a multicenter Berubicin Phase 2 adult GBM trial and a multicenter pediatric Phase 1 malignant glioma trial. “WPD plans to…

TuesdayMar 16, 2021 2:34 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants

Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma (“GBM”) patients Glioblastomas are a type of brain cancer that have continued to elude effective therapy over the past century of investigation, leaving patients with expectations of approximately 15 months of survivability beyond diagnosis and recurrence after surgical removal A GBM patient in a small Phase 1 Berubicin safety trial 15 years ago has remained cancer-free and stable as of last November, a hint of…

MondayMar 15, 2021 12:43 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in First-Ever Emerging Growth Virtual Conference

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco will be presenting at the inaugural Emerging Growth Virtual Conference. Scheduled for March 17–18, the virtual conference is presented by M Vest LLC and Maxim Group LLC. The conference agenda includes roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A’s, and presentations from hundreds of issuers both domestically and internationally. CNS Pharmaceuticals is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, and Climaco’s presentation will include an overview of the company. In addition…

WednesdayMar 10, 2021 11:17 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leverages ‘Absolute Powerhouse Compound’ as IND Status Paves Way for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco, in a recent podcast, showed his excitement at news that the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status. The IND designation clears the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said of the significant milestone. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP